1. Introduction
===============

Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disorder of the kidneys characterized by markedly enlarged kidneys with extensive cyst formation throughout. As kidney function diminishes with age, these cysts progressively enlarge.^\[[@R1]\]^ ADPKD is a systemic disorder, and cysts appear in the kidneys, liver, pancreas, brain, spleen, ovaries, and testes. Other disorders associated with ADPKD include inguinal and abdominal hernias, cardiac valvular disorders, and aneurysms of coronary arteries, the aorta, and cerebral arteries.^\[[@R2]\]^

The prevalence of renal cell carcinoma (RCC) in patients with ADPKD is known to be high.^\[[@R3]\]^ Whether this is due to chronic dialysis or the underlying disease is still speculative, but attending physicians should be aware of the malignant potential of ADPKD, especially in patients receiving concomitant dialysis.^\[[@R4]\]^ The most common histological types of kidney tumors are clear cell RCC (ccRCC, 75%), type I papillary RCC (5%), type II papillary RCC (10%), and chromophobe RCC and oncocytoma (10%).^\[[@R5]\]^

Meanwhile, many reports have described genetic alterations in RCC. In roughly 95% of ccRCC cases, the short arm of chromosome 3 (3p) is lost; therefore, loss of 3p is the most frequent genetic alteration linked to ccRCC development. Gain of 5q (occurring in 69% of cases), partial loss of 14q (occurring in 42% of cases), gain of 7q (occurring in 20% of cases), loss of 8p (occurring in 32% of cases), and deletion of 9p (occurring in 29% of cases) are less frequent in ccRCC than loss of 3p, but are nonetheless important genetic alterations in ccRCC. On the level of genes, *MTOR 1, 8, KDM5C, BAP-1, SETD2, PBRM-1*, and *VHL* have been linked to the pathogenesis of ccRCC.^\[[@R6]\]^ However, the pathogenic gene alterations in RCC occurring in patients with ADPKD are poorly understood.

G-coupled protein receptors (GPCRs) and Wnt/ β-catenin signaling are among the numerous signaling pathways that appear to be involved in ADPKD, as are mammalian target of rapamycin (mTOR), B-Raf/ERK, mitogen-activated protein kinase (MAPK), activator protein-1 (AP-1) transcription factor, RKIP, and second messengers including Ca^2+^ and cAMP.^\[[@R7]\]^ Nonetheless, little is known about changes in signaling pathways in RCC in patients with ADPKD.

However, there was a report of dysregulation of catenin signaling in RCC in a patient with Von Hippel-Lindau (VHL) syndrome, which also predisposes patients to the development of polycystic kidney disease, like ADPKD. That study suggested that disruption of this signaling pathway may be the link between RCC and polycystic kidney disease.^\[[@R8]\]^

We conducted a comprehensive analysis based on whole exome and transcriptome sequencing using blood, cyst, and RCC tissue obtained from an AKPKD patient. Through this analysis, we attempted to identify specific genetic alterations and changes in signaling pathways in RCC in a patient with ADPKD.

2. Materials and methods
========================

2.1. Patient
------------

A 68-year-old male ADPKD patient presented to a tertiary hospital for treatment of a left renal mass that was incidentally detected on a computed tomography (CT) scan. An early enhanced-washout nodule measuring 2.4 × 2.7 × 2.7 cm was seen in the left kidney interpolar area, and was suspected to be RCC with no involvement of other adjacent organs or lymph nodes (Fig. [1](#F1){ref-type="fig"}). The decision was made to perform left partial nephrectomy, and the patient was admitted to the urology department.

![Renal cell carcinoma measuring 2.4 × 2.7 × 2.7 cm in the left kidney on a CT scan. An early enhanced-washout mass measuring 2.4 × 2.7 × 2.7 cm was found on abdominopelvic CT in the left kidney interpolar area and was suspected to be renal cell carcinoma.](medi-99-e20071-g001){#F1}

After surgery, an RCC with a negative margin was identified from the intraoperative frozen section biopsy (Fig. [2](#F2){ref-type="fig"}). The final pathological diagnosis was ccRCC.

![Renal cell carcinoma measuring 2.7 cm. The patient underwent partial nephrectomy and margin-negative renal cell carcinoma was confirmed from the frozen section biopsy. The final pathological diagnosis was clear cell RCC.](medi-99-e20071-g002){#F2}

The study protocol was approved by the Institutional Review Board of Chuncheon Sacred Heart Hospital (IRB number CHUNCHEON 2017-11-106-008). The study protocol conformed to ethical guidelines of the World Medical Association Declaration of Helsinki.

2.2. Whole exome sequencing and analysis
----------------------------------------

Genomic DNA was extracted from the peripheral blood of the patient and from the cyst and tumor tissue of the removed kidney, and exome regions were captured in each sample using Agilent\'s SureSelect Human All Exon V5-post (Agilent Technologies, Santa Clara, CA). Exome sequencing was performed on an Illumina HiSeq 2500 platform (Illumina, San Diego, CA). Sequencing reads were aligned to the hg19 reference genome with the Burrows-Wheeler Aligner v0.7.5,^\[[@R9]\]^ using the MEM algorithm. The aligned reads were processed, with sorting, de-duplication, local realignment, and base recalibration performed using SAMtools v1.2,^\[[@R10]\]^ Picard tools v1.127 (<https://broadinstitute.github.io/picard/>), and the Genome Analysis Tool Kit (GATK) v3.8,^\[[@R11]\]^ respectively (Fig. [3](#F3){ref-type="fig"}A).

![WES and WTS pipeline. (A) Genomic DNA was extracted and exome regions were captured in each sample. The aligned reads were processed, with sorting, de-duplication, local realignment, and base recalibration performed. (B) mRNA was isolated, captured, sequenced, and aligned. The aligned reads were assembled to known or novel transcripts. Possible fusion genes were predicted. CNV = copy number variation, INDEL = insertions, and deletions, SNV = single-nucleotide variants, SV = structural variants, WES and WTS = whole exome sequencing and whole transcriptome sequencing and analysis.](medi-99-e20071-g003){#F3}

Germline or somatic variants, including single-nucleotide variants, insertions, and deletions, were called by the haplotype caller of GATK, MuTect2,^\[[@R12]\]^ VarScan v2.3.6,^\[[@R13]\]^ and Pindel v0.2.5a4,^\[[@R14]\]^ and annotated minor allele frequency and clinical information were obtained from public databases, such as the Catalogue of Somatic Mutations in Cancer (COSMIC), Exome Aggregation Consortium (ExAC), the 1000 Genomes Project (1000G), and ClinVar, as well as prediction tools such as SIFT, PolyPhen-2, MutationTaster, and GERP++ by ANNOVAR.^\[[@R15]\]^ Structural variants and copy number alterations were calculated by an in-house method (referred to as JuLI) and EXCAVATOR^\[[@R16]\]^ in paired mode, respectively (Fig. [4](#F4){ref-type="fig"}). Detected variants were prioritized as previously described (submitted).

![Variant calling and analysis pipeline by *Targeted exome sequencing* Germline or somatic variants, including single-nucleotide variants, insertions, and deletions, were called and annotated minor allele frequency and clinical information. A previously reported database was referenced and the variants were classified into 6 categories.](medi-99-e20071-g004){#F4}

2.3. Whole transcriptome sequencing and analysis
------------------------------------------------

mRNA isolated from peripheral blood and cyst and tumor tissue was processed, captured using the TruSeq RNA Access Library (Illumina, San Diego, CA), and sequenced on the HiSeq 2500 platform (Illumina, San Diego, CA). RNA sequencing reads were aligned to hg19 in the default mode of Tophat v2.0.13.^\[[@R17]\]^ The aligned reads were assembled to known or novel transcripts using the RABT algorithm in Cufflinks v2.2.1.^\[[@R18]\]^ Possible fusion genes were predicted using the clustering method of spanning reads and split reads and the heuristic filter of deFuse 0.6.2 (Fig. [3](#F3){ref-type="fig"}B).^\[[@R19]\]^

To identify mutations at the transcriptome level, RNA sequencing reads were mapped to hg19 with STAR v2.4.0f1.^\[[@R20]\]^ Aligned reads were marked as duplicates, trimmed adaptor sequences, indel realignment, and base recalibration using Trimmomatic v0.32,^\[[@R21]\]^ as well as SAMtools, Picard tools, and GATK as described above. Variants were called using the haplotype caller of GATK.

Aligned RNA-Seq reads were calculated as fragments per kilobase of exon per million fragments mapped (FPKM) at the gene or transcript level. After a quality control process that involved filtering out zero-count genes, logarithm-2-based transformation, and quantile normalization, a differentially expressed gene (DEG) analysis of 18,633 genes was performed between the tumor samples and normal blood, and 3284 genes showed a significant differential expression pattern, as indicated by an absolute fold change above 2. We performed gene set enrichment analyses (GSEA)^\[[@R22],[@R23]\]^ to identify significant patterns of differential expression in Kyoto Encyclopedia of Genes and Genomes (KEGG)^\[[@R24]\]^ pathways and in Gene Ontology (GO).^\[[@R25],[@R26]\]^ We set the significance threshold as a false discovery rate (FDR) below 0.05.

3. Results
==========

3.1. Causal germline mutation of ADPKD
--------------------------------------

To diagnose ADPKD, we examined the sequences of *PKD1* and *PKD2* from the blood samples, and detected a nonsense *PKD2* mutation, R742X, which is well known as a definitely pathogenic variant in ADPKD.^\[[@R27]\]^ In a functional study, it was found that this nonsense *PKD2* mutation results in an absence of the C-terminal region containing the coiled-coil domain, which causes failure to create the polycystin-1 and polycystin-2 complex that regulates Ca2+, Na+, and K+ concentration as a Ca2+-regulated non-selective cation channel in renal epithelial cells.^\[[@R28]\]^

3.2. Germline and somatic mutations of RCC
------------------------------------------

We performed whole exome sequencing for paired samples of tumor tissue, cyst tissue, and peripheral blood from the patient, and identified germline and somatic mutations in the blood and tumor tissues. First, we found several germline and somatic mutations in genes including *DNAH5*, *KMT5A*, *CCDC175*, and *TPSAB1* from the blood, tumor, and cyst of the patient (Table [1](#T1){ref-type="table"}). Next, we investigated mutations in known oncogenes and tumor suppressor genes in RCC. In particular, eight of 19 genes (*VHL*, *PBRM1*, *SETD2*, *KDM5C*, *PTEN*, *BAP1*, *MTOR*, and *TP53*) were found to be extremely significantly mutated (FDR \< 0.1 and *q* \< 0.00001) in RCC in a previous study.^\[[@R29]\]^ In this case, a missense *VHL* mutation, S65L, which has been reported to lead to tumorigenesis by disrupting the dynamic organization of pVHL and HIF-1α for ubiquitin-dependent degradation,^\[[@R30]\]^ was only detected in tumor tissue, not blood or cyst samples (Table [1](#T1){ref-type="table"}). Furthermore, a novel missense *SMARCA4* mutation (K981T) was also detected. *SMARCA4* is a known tumor suppressor that encodes BRG1, which is an ATPase enzymatic subunit of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex in RCC.

###### 

Germline and somatic mutations in an ADPKD patient with RCC.

![](medi-99-e20071-g005)

3.3. Somatic copy number alterations of RCC
-------------------------------------------

The global characterization of somatic copy number alterations (SCNAs) in RCC was previously analyzed, and it was found that SCNAs occurred at fewer sites in RCC than in other cancers, and that more SCNAs involved whole chromosomes or arm-level alterations than focal events. Frequent patterns of SCNAs in RCC were found to include loss of chromosome 3p and 14q or gain of chromosome 5q at the arm level, as well as gain of 5q35, 8q24, 3q26, and 1q32 or loss of 14q24, 9p21.3, 6q26, 8p11, 10q23, 1p36, 4q35, 13q21, 15q21, and 2q37 at the focal level.^\[[@R29]\]^ Based on these previous studies, we analyzed SCNAs using EXCAVATOR in paired-end mode between blood and tumor whole exome sequencing. First, loss of chromosome 3p, which is the most commonly involved pattern (frequency: 95% in ccRCC) at the arm level, was detected. This region contains VHL, where a missense mutation, S65L, was detected in this patient\'s tumor, as well as *PBRM1*, *BAP1*, *SETD2*, and *CADM2*, which are known to be the most frequently mutated genes in RCC, as described above, and are putative tumor suppressor genes. Next, gain of 1q21--23.1, 7p22.2--22.3, 13q14.11, and 13q34 at the focal level, which is not a known pattern in RCC, was detected (Table [2](#T2){ref-type="table"}). Taken together, we found that double somatic mutations---the missense mutation S65L and the loss of chromosome 3p---occurred at *VHL*, a tumor suppressor gene, in the tumor tissue of the ADPKD patient. The loss of function of *VHL* might have influenced the development of RCC in this ADPKD patient.

###### 

Somatic copy number variants detected in paired tumor-cyst samples.
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Since tumor purity was calculated as about 60% by our in-house method, we were able to determine the normalized variant allele fractions (VAFs) of each genotype of somatic mutations. The loss-of-heterozygosity of the *VHL* mutation was called as a heterozygous variant with 45% VAF, which was normalized to 100% VAF with the loss of chromosome 3p, where *VHL* is located.

3.4. RNA expression patterns in the patient
-------------------------------------------

Gene set enrichment analyses (GSEA) detected significance in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 255 and for Gene Ontology (GO) term 4475 (Supplementary Tables 1 and 2). Especially, metabolic pathways, focal adhesion, the PI3K-Akt signaling pathway, and cancer pathways were the top-ranked pathways ordered by false discovery rate (FDR). Additionally, the RCC included 14 genes reported to be significantly differentially expressed in tumors in the KEGG database. Specifically, angiogenesis in tumors seemed to be upregulated through the VEGF signaling pathway resulting from the loss of VHL. Moreover, proliferation was expected to be activated by the MAPK signaling pathway, including *NRAS* and *MAPK1* expression (Supplementary Table 2).

4. Discussion
=============

In the present study, we found loss of function of the *VHL* gene, including 3p deletion combined with a missense mutation in RCC, in a patient with ADPKD, not VHL syndrome. The causal mutation of ADPKD was a PKD2 truncating mutation. We also found several germline and somatic mutations, including *SMARCA4* (K981T), a novel missense mutation. In the transcriptome analysis, we found that angiogenesis seemed to be accelerated through the upregulation of the VEGF signaling pathway in RCC.

In this study, we investigated the mRNA expression of genes related to RCC and found that several genes were upregulated or downregulated. In this case, angiogenesis might have been activated by the VEGF pathway. VEGF binding to its receptor leads to signaling via the PI3K/AKT, Raf/MAPK, PLC, and Src pathways, resulting in increased cell permeability, endothelial cell proliferation, migration, and survival through angiogenesis. VEGF expression in cancer is elevated in response to tissue hypoxia, as a result of mutations of the *VHL* gene. It is known that HIF1, which activates VEGF, is degraded by the *VHL* gene product.^\[[@R30]\]^ In the case described in the presentt study, the possibility of overexpression of VEGF by HIF1, which was not degraded due to the loss of function of *VHL*, can be considered. In addition, TGF-\< can accelerate tumorigenesis through cell proliferation, and TGF- is known to induce apoptosis and differentiation. In this study, TGF-\< was upregulated in the tumor and TGF- was downregulated, which might have caused RCC.

VHL syndrome is a neoplastic disorder inherited in an autosomal dominant manner that manifests through tumor development in a broad range of tissues, including the kidneys, adrenal glands, pancreas, inner ear, retina, spine, and cerebellum. The bilateral multifocal renal tumors that can occur in association with VHL syndrome are malignant and capable of metastasis. The risk posed by such tumors is underscored by the fact that in the past, as many of 40% of untreated patients with VHL syndrome died of advanced ccRCC. It is known that the frequency of sporadic RCC increases with loss of function of the *VHL* tumor suppressor gene in VHL syndrome. In this report, we showed a case of ccRCC caused by loss of function of the *VHL* gene, which co-existed with a PKD2 truncating mutation that was the causative gene of ADPKD. -catenin is known to be the linkage between RCC and PKD. Similarly, VEGF may be a linkage between RCC and PKD, so further efforts should be made to elucidate the pathogenesis.

mTOR is considered to be the master regulator of cell growth. Upon receiving growth signals, mTOR promotes several anabolic processes in which macromolecules are synthesized, thereby increasing cellular biomass, and limits catabolic processes such as autophagy.^\[[@R31]\]^ The mTOR signal pathway is dysregulated in some common types of cancer, including renal cancer, and abnormal activity of mTOR was shown in ADPKD. Taken together, the incidence of kidney cancer is closely associated with ADPKD.

Polycystin-1, the *PKD1* gene product, regulates G0/G1 of the cell cycle by serving as a regulator of the G1 checkpoint; thus, immature G1 exit occurs in ADPKD. It has also been found that oxidative stress plays an major role in ADPKD. Therefore, the occurrence of somatic mutations in ADPKD might be caused by immature G1 exit and DNA damage through oxidative stress.

A major strength of this study is that it presents the first finding of loss of function in the *VHL* gene in RCC in a patient with ADPKD. The primary limitation of this study is that in selected pathways, the mRNA dose was not equal to the protein expression dose. Therefore, experimental support of the upregulated pathway is needed.

5. Conclusion
=============

In this study, we investigated a Korean ADPKD patient with RCC and found some somatic mutations in tumor suppressor genes and oncogenes using whole exome sequencing. In conclusion, loss of function of the *VHL* gene can be a causative genetic alteration in RCC with ADPKD. VEGF, mTOR, and oxidative stress could be accelerators of kidney cancer in patients with ADPKD.
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